Literature DB >> 24926545

Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.

Erick Riquelme1, Milind B Suraokar1, Jaime Rodriguez1, Barbara Mino1, Heather Y Lin2, David C Rice3, Anne Tsao4, Ignacio I Wistuba5.   

Abstract

INTRODUCTION: Malignant pleural mesothelioma (MPM) is a deadly disease with poor prognosis and few treatment options. We characterized and elucidated the roles of C-MYC and PVT1 involved in the pathogenesis of MPM.
METHODS: We used small interfering RNA (siRNA)-mediated knockdown in MPM cell lines to determine the effect of C-MYC and PVT1 abrogation on MPM cells undergoing apoptosis, proliferation, and cisplatin sensitivity. We also characterized the expression of microRNAs spanning the PVT1 region in MPM cell lines. Copy number analysis was measured by quantitative polymerase chain reaction and fluorescence in situ hybridization.
RESULTS: Copy number analysis revealed copy number gains (CNGs) in chromosomal region 8q24 in six of 12 MPM cell lines. MicroRNA analysis showed high miR-1204 expression in MSTO-211H cell lines with four copies or more of PVT1. Knockdown by siRNA showed increased PARP-C levels in MSTO-211H transfected with siPVT1 but not in cells transfected with siC-MYC. C-MYC and PVT1 knockdown reduced cell proliferation and increased sensitivity to cisplatin. Analysis of the expression of apoptosis-related genes in the MSTO-211H cell line suggested that C-MYC maintains a balance between proapoptotic and antiapoptotic gene expression, whereas PVT1 and, to a lesser extent, miR-1204 up-regulate proapoptotic genes and down-regulate antiapoptotic genes. Fluorescence in situ hybridization analysis of MPM tumor specimens showed a high frequency of both CNGs (11 of 75) and trisomy (three copies; 11 of 75) for the C-MYC locus.
CONCLUSION: Our results suggest that C-MYC and PVT1 CNG promotes a malignant phenotype of MPM, with C-MYC CNG stimulating cell proliferation and PVT1 both stimulating proliferation and inhibiting apoptosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24926545      PMCID: PMC4287384          DOI: 10.1097/JTO.0000000000000202

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  34 in total

1.  Analysis of current trends in United States mesothelioma incidence.

Authors:  B Price
Journal:  Am J Epidemiol       Date:  1997-02-01       Impact factor: 4.897

Review 2.  The pathogenesis of mesothelioma.

Authors:  Michele Carbone; Robert A Kratzke; Joseph R Testa
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

3.  Miz1 is required for early embryonic development during gastrulation.

Authors:  Sovana Adhikary; Karen Peukert; Holger Karsunky; Vincent Beuger; Werner Lutz; Hans-Peter Elsässer; Tarik Möröy; Martin Eilers
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

4.  Changing trends in US mesothelioma incidence.

Authors:  H Weill; J M Hughes; A M Churg
Journal:  Occup Environ Med       Date:  2004-05       Impact factor: 4.402

5.  Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.

Authors:  Yinghui Guan; Wen-Lin Kuo; Jackie L Stilwell; Hirokuni Takano; Anna V Lapuk; Jane Fridlyand; Jian-Hua Mao; Mamie Yu; Melinda A Miller; Jennifer L Santos; Steve E Kalloger; Joseph W Carlson; David G Ginzinger; Susan E Celniker; Gordon B Mills; David G Huntsman; Joe W Gray
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

Review 6.  The interplay between MYC and HIF in cancer.

Authors:  Chi V Dang; Jung-whan Kim; Ping Gao; Jason Yustein
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

7.  The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells.

Authors:  Letizia Carramusa; Flavia Contino; Arianna Ferro; Luigi Minafra; Giovanni Perconti; Agata Giallongo; Salvatore Feo
Journal:  J Cell Physiol       Date:  2007-11       Impact factor: 6.384

Review 8.  Malignant pleural mesothelioma.

Authors:  Anne S Tsao; Ignacio Wistuba; Jack A Roth; Hedy Lee Kindler
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

9.  Chromosome 8 breakpoint far 3' of the c-myc oncogene in a Burkitt's lymphoma 2;8 variant translocation is equivalent to the murine pvt-1 locus.

Authors:  M Graham; J M Adams
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

10.  A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression.

Authors:  Kerstin B Meyer; Ana-Teresa Maia; Martin O'Reilly; Maya Ghoussaini; Radhika Prathalingam; Patricia Porter-Gill; Stefan Ambs; Ludmila Prokunina-Olsson; Jason Carroll; Bruce A J Ponder
Journal:  PLoS Genet       Date:  2011-07-21       Impact factor: 5.917

View more
  51 in total

Review 1.  The bright side of dark matter: lncRNAs in cancer.

Authors:  Joseph R Evans; Felix Y Feng; Arul M Chinnaiyan
Journal:  J Clin Invest       Date:  2016-08-01       Impact factor: 14.808

2.  Kanglaite inhibits the expression of drug resistance genes through suppressing PVT1 in cisplatin-resistant gastric cancer cells.

Authors:  Xian-Wen Zhang; Liang Liu; Xi-Zhi Zhang; Ping Bo
Journal:  Exp Ther Med       Date:  2017-06-22       Impact factor: 2.447

3.  LncRNA PVT1 overexpression is a poor prognostic biomarker and regulates migration and invasion in small cell lung cancer.

Authors:  Chengsuo Huang; Shuguang Liu; Huijun Wang; Zicheng Zhang; Qing Yang; Fang Gao
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

4.  Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.

Authors:  Alain C Borczuk; Jianming Pei; Robert N Taub; Brynn Levy; Odelia Nahum; Jinli Chen; Katherine Chen; Joseph R Testa
Journal:  Cancer Biol Ther       Date:  2016-02-06       Impact factor: 4.742

5.  Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.

Authors:  Eleonora Sementino; Craig W Menges; Yuwaraj Kadariya; Suraj Peri; Jinfei Xu; Zemin Liu; Richard G Wilkes; Kathy Q Cai; Frank J Rauscher; Andres J Klein-Szanto; Joseph R Testa
Journal:  J Cell Physiol       Date:  2018-06-15       Impact factor: 6.384

6.  Non-Coding RNA Pvt1 Promotes Cancer Stem Cell-Like Traits in Nasopharyngeal Cancer via Inhibiting miR-1207.

Authors:  Meng Cui; Yu Chang; Qi-Gen Fang; Wei Du; Jun-Fu Wu; Ji-Heng Wang; Shan-Ting Liu; Su-Xia Luo
Journal:  Pathol Oncol Res       Date:  2018-08-23       Impact factor: 3.201

7.  p53 Activates the Long Noncoding RNA Pvt1b to Inhibit Myc and Suppress Tumorigenesis.

Authors:  Christiane E Olivero; Elena Martínez-Terroba; Joshua Zimmer; Clara Liao; Ephrath Tesfaye; Nima Hooshdaran; Jeremy A Schofield; Jordan Bendor; Dorthy Fang; Matthew D Simon; Jesse R Zamudio; Nadya Dimitrova
Journal:  Mol Cell       Date:  2020-01-20       Impact factor: 17.970

8.  Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.

Authors:  Mahadev Rao; Scott M Atay; Vivek Shukla; Young Hong; Trevor Upham; R Taylor Ripley; Julie A Hong; Mary Zhang; Emily Reardon; Patricia Fetsch; Markku Miettinen; Xinmin Li; Cody J Peer; Tristan Sissung; William D Figg; Assunta De Rienzo; Raphael Bueno; David S Schrump
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

Review 9.  Long non-coding RNA PVT1: Emerging biomarker in digestive system cancer.

Authors:  Dan-Dan Zhou; Xiu-Fen Liu; Cheng-Wei Lu; Om Prakash Pant; Xiao-Dong Liu
Journal:  Cell Prolif       Date:  2017-10-12       Impact factor: 6.831

10.  Cancer RNA-Seq Nexus: a database of phenotype-specific transcriptome profiling in cancer cells.

Authors:  Jian-Rong Li; Chuan-Hu Sun; Wenyuan Li; Rou-Fang Chao; Chieh-Chen Huang; Xianghong Jasmine Zhou; Chun-Chi Liu
Journal:  Nucleic Acids Res       Date:  2015-11-23       Impact factor: 19.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.